|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
With respect to the new methods of detecting minimal residual disease (MRD) in lymphoid malignancies utilizing PCR-mediated amplification of the junctional regions of TcR genes, our data indicate that this MRD-PCR analysis will generally be more sensitive if TcR-delta instead of TcR-gamma junctional-region-specific probes are used.
|
1837811 |
1991 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We report the retrospective follow-up of MRD in bone marrow (BM) samples from 50 childhood B-precursor ALL patients by IgH/TCR delta PCR.
|
7564517 |
1995 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We have compared the kinetics of minimal residual disease (MRD) by simultaneous polymerase chain reaction (PCR) monitoring with oligonucleotides for the immunoglobulin heavy chain (IgH) complementarity-determining region 3 (CDR3) and the T-cell receptor gamma chain gene (TCR gamma), as well as clone-specific CDR3 sequences in adult patients (aged 17-51 years) with acute lymphoblastic leukemia (ALL) who entered a complete hematological remission (CR) after chemotherapy with the German multicenter ALL (GMALL) protocol.
|
7578520 |
1995 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Crosslineage T-cell receptor delta (TCR delta) rearrangements are widely used as tumor markers for the follow up of minimal residual disease in childhood B-precursor acute lymphoblastic leukemia (ALL) by polymerase chain reaction (PCR).
|
7606000 |
1995 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Tumour-specific oligoprobes were developed against the single V1-J1 rearrangement of the delta T-cell receptor (TCR) gene in order to perform minimal residual disease (MRD) studies.
|
7669677 |
1995 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Junctional sequences of immunoglobulin (Ig)/T-cell receptor (TCR) gene rearrangements are used as patient-specific PCR targets for the detection of minimal residual disease (MRD) in acute lymphoblastic leukaemias (ALLs).
|
7786801 |
1995 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
|
7845021 |
1995 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The use of both delta and gamma TCR genes as clonal markers, as well as simplification in the methods to detect and quantify residual blasts reported here, will allow the study of the large number of patients required to determine the role of the detection of minimal residual disease by PCR in the follow-up of childhood ALL.
|
8142656 |
1994 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The heterogeneity reported here in Ig and/or TcR gene rearrangement patterns at diagnosis and relapse might hamper polymerase chain reaction (PCR)-mediated detection of minimal residual disease (MRD) using junctional regions of rearranged Ig or TcR genes as PCR targets.
|
8161789 |
1994 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Direct sequence analysis of TCR V delta 2-D delta 3 rearrangements in common acute lymphoblastic leukaemia and application to detection of minimal residual disease.
|
8217823 |
1993 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To date, the main leukemia-specific DNA sequences used as PCR targets in detection of MRD are breakpoint fusion regions of chromosome translocations and junctional regions of rearranged immunoglobulin (Ig) or T-cell receptor (TcR) genes.
|
8255100 |
1993 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cases in which minimal residual disease (MRD) became undetectable were cross-controlled using either TCR delta rearrangement or a specific translocation to circumvent the problem of false-negative results arising from clonal evolution.
|
8364210 |
1993 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
By screening for immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in bone marrow samples aspirated at different time points during the course of disease from 43 patients with acute leukaemia we have analysed the extent of clonal evolution after autologous bone marrow transplantation (ABMT) and addressed the issue of whether the Southern Blot method has the power to reveal clonal proliferations representing minimal residual disease (MRD) in the autologous bone marrow grafts.
|
8698127 |
1996 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Using IgH and TCR gamma gene rearrangements as gene markers, we detected minimal residual disease (MRD) by means of the polymerase chain reaction (PCR) and restriction analysis.
|
8735342 |
1996 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Several means of analyzing minimal residual disease (MRD) in leukemia involving the rearranged T cell receptor (TCR) gene have been described.
|
9111164 |
1997 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We also evaluated whether heteroduplex analysis of polymerase chain reaction (PCR) products of rearranged Ig and TCR genes can be used for identification of molecular targets for minimal residual disease (MRD) detection.
|
9665194 |
1998 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe.
|
9844931 |
1998 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The occurrence of the different types of TCRB rearrangement patterns has implications for PCR-based clonality assessment and for PCR-based detection of minimal residual disease via TCRB gene analysis.
|
10360387 |
1999 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The chimeric status of BMT recipients was compared to minimal residual disease (MRD) detection by analysis of immunoglobulin heavy chain (IgH) and T cell receptor (TcR) genes.
|
10808205 |
2000 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A successful MRD detection approach requires a stable marker and for lymphoid leukemias clonal rearrangements of immunoglobulin (Ig) and T cell receptor (TCR) genes are commonly used.
|
11684274 |
2001 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The CDR-3 region of heavy-chain immunoglobulin has been used as a clonal marker in the study of minimal residual disease in children with acute lymphoblastic leukemia.
|
11723528 |
2001 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We investigated whether the MRD results obtained using RT-PCR of TEL-AML1 transcripts correlated with the clinically validated genomic PCR for Ig and TCR gene rearrangements.
|
11841400 |
2002 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clonal Ig and TCR targets for MRD detection were identified in 94 patients, with 71% of these targets being preserved at relapse.
|
11895762 |
2002 |
|
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
|
11896540 |
2002 |
|
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The strategy used for IgH-ASO and TCR-ASO RQ-PCR assays is accurate and reliable in the clinical prospective study of MRD in childhood lymphoid malignancies.
|
11939263 |
2002 |